5GZO

Structure of neutralizing antibody bound to Zika envelope protein

5GZO の概要

• エントリーDOI: 10.2210/pdb5gzo/pdb
• 関連するPDBエントリー: 5GZN
• 分子名称: Genome polyprotein, Antibody heavy chain, Antibody light chain (3 entities in total)
• 機能のキーワード: zika virus, human neutralizing antibodies, envelope protein, molecular determinants, viral protein-immune system complex, viral protein/immune system
• 由来する生物種: Zika virus (ZIKV); 詳細
• 細胞内の位置: Virion membrane ; Multi-pass membrane protein : H9A910
• タンパク質・核酸の鎖数: 6
• 化学式量合計: 182761.19

構造登録者

Wang, Q.,Yang, H.,Liu, X.,Dai, L.,Ma, T.,Qi, J.,Wong, G.,Peng, R.,Liu, S.,Li, J.,Li, S.,Song, J.,Liu, J.,He, J.,Yuan, H.,Xiong, Y.,Liao, Y.,Li, J.,Yang, J.,Tong, Z.,Griffin, B.,Bi, Y.,Liang, M.,Xu, X.,Cheng, G.,Wang, P.,Qiu, X.,Kobinger, G.,Shi, Y.,Yan, J.,Gao, G.F. (登録日: 2016-09-29, 公開日: 2017-01-18, 最終更新日: 2024-10-16)

主引用文献

Wang, Q.,Yang, H.,Liu, X.,Dai, L.,Ma, T.,Qi, J.,Wong, G.,Peng, R.,Liu, S.,Li, J.,Li, S.,Song, J.,Liu, J.,He, J.,Yuan, H.,Xiong, Y.,Liao, Y.,Li, J.,Yang, J.,Tong, Z.,Griffin, B.D.,Bi, Y.,Liang, M.,Xu, X.,Qin, C.,Cheng, G.,Zhang, X.,Wang, P.,Qiu, X.,Kobinger, G.,Shi, Y.,Yan, J.,Gao, G.F.
Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus
Sci Transl Med, 8:369ra179-369ra179, 2016

PubMed Abstract: The 2015-2016 outbreak of Zika virus (ZIKV) disease has affected many countries and is a major public health concern. ZIKV is associated with fetal microcephaly and neurological complications, and countermeasures are needed to treat and prevent ZIKV infection. We report the isolation of 13 specific human monoclonal antibodies from a single patient infected with ZIKV. Two of the isolated antibodies (Z23 and Z3L1) demonstrated potent ZIKV-specific neutralization in vitro without binding or neutralizing activity against strains 1 to 4 of dengue virus, the closest relative to ZIKV. These two antibodies provided postexposure protection to mice in vivo. Structural studies revealed that Z23 and Z3L1 bound to tertiary epitopes in envelope protein domain I, II, or III, indicating potential targets for ZIKV-specific therapy. Our results suggest the potential of antibody-based therapeutics and provide a structure-based rationale for the design of future ZIKV-specific vaccines.

PubMed: 27974667
DOI: 10.1126/scitranslmed.aai8336

実験手法

X-RAY DIFFRACTION (2.755 Å)